BHC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BHC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bausch Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $452 Mil. Bausch Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $21,208 Mil. Bausch Health's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $-1,175 Mil. Bausch Health's debt to equity for the quarter that ended in Jun. 2024 was -18.43.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bausch Health's Debt-to-Equity or its related term are showing as below:
During the past 13 years, the highest Debt-to-Equity Ratio of Bausch Health was 51.39. The lowest was -213.72. And the median was 4.98.
The historical data trend for Bausch Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial | 24.36 | 44.72 | -213.72 | -30.01 | -21.91 |
Bausch Health Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Debt-to-Equity | Get a 7-Day Free Trial | -31.00 | -19.01 | -21.91 | -19.80 | -18.43 |
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bausch Health's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Bausch Health's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (450 | + | 21938) | / | -1022 | |
= | -21.91 |
Bausch Health's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (452 | + | 21208) | / | -1175 | |
= | -18.43 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (NYSE:BHC) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Bausch Health's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Seana Carson | officer: EVP, General Counsel | 400 SOMERSET CORPORATE BLVD, BRIDGEWATER NJ 08807 |
John S Barresi | officer: SVP, Controller & CAO | 727 FIFTH AVENUE, NEW YORK NY 10022 |
Richard Mulligan | director | C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153 |
Tom George Vadaketh | officer: EVP, Chief Financial Officer | 1727 JOCKEYS WAY, YARDLEY PA 19067 |
Robert Spurr | director, officer: U.S. President-Pharma Business | C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Joseph F Gordon | officer: Pres&Co-Head Bausch&Lomb/Int'l | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Frederick Munsch | officer: SVP, Controller and CAO | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Christina Ackermann | officer: EVP AND GENERAL COUNSEL | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Sam Eldessouky | officer: EVP & Chief Financial Officer | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Steven D Miller | director | 16690 COLLINS AVENUE, PH, SUNNY ISLE BEACH FL 33160 |
Von Eschenbach Andrew C. | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
De Schutter Richard U | director | C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807 |
Brett Icahn | director | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160 |
William D. Humphries | officer: EVP, COMPANY GROUP CHAIRMAN | C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044 |
Valueact Capital Master Fund, L.p. | director, other: See remarks | ONE LETTERMAN DRIVE, BUILDING D, 4TH FLOOR, SAN FRANCISCO CA 94129 |
From GuruFocus
By GuruFocus Research • 05-02-2024
By GuruFocus Research • 08-01-2024
By ACCESSWIRE • 06-14-2024
By ACCESSWIRE • 02-12-2024
By ACCESSWIRE • 04-12-2024
By GuruFocus Research • 02-22-2024
By ACCESSWIRE • 04-11-2024
By GuruFocus Research • 02-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.